Eleven Biotherapeutics Inc. (EBIO) Shares Down 3.5%
Eleven Biotherapeutics Inc. (NASDAQ:EBIO)’s share price fell 3.5% on Wednesday . The company traded as low as $4.98 and last traded at $5.01, with a volume of 624,566 shares trading hands. The stock had previously closed at $5.19.
The company’s market capitalization is $73.58 million. The firm’s 50-day moving average price is $3.58 and its 200-day moving average price is $1.62.
Eleven Biotherapeutics (NASDAQ:EBIO) last issued its quarterly earnings data on Friday, August 12th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter. Equities research analysts expect that Eleven Biotherapeutics Inc. will post ($1.75) earnings per share for the current fiscal year.
In other Eleven Biotherapeutics news, major shareholder Boxer Capital, Llc sold 1,042,000 shares of Eleven Biotherapeutics stock in a transaction on Monday, June 13th. The stock was sold at an average price of $2.74, for a total value of $2,855,080.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Eleven Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.